Glaxo Lacks Diversified Drug Portfolio: Rundquist

Glaxo Lacks Diversified Drug Portfolio: Rundquist Play

July 24 (Bloomberg) -- Odile Rundquist, senior analyst at Helvea, previews quarterly results from Glaxo Smithkline, looks at the impact of the drugmaker's recent troubles in China and compares the U.S. and European pharma sectors. She speaks on Bloomberg Television's "On The Move."

  • On Air Now

    Bloomberg Surveillance Watch Now

  • Next

    In The Loop with Betty Liu

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

blog comments powered by Disqus